Introduction {#s1}
============

Fibrosis, characterized by excess accumulation of extracellular matrix (ECM), is a common pathological process in many chronic diseases or injuries. Many irritations trigger the pro-fibrotic responses, including persistent infections, radiation, chemical agents, genetic disorders, and autoimmune diseases. The development of fibrosis is accompanied by the loss of a fraction of resident cells and their replacement by ECM, which would finally lead to tissue remodeling and organ failure. Fibrosis contributes to high morbidity and mortality in many diseases such as dilated cardiomyopathy and idiopathic pulmonary fibrosis (IPF) (Gulati et al., [@B58]; Hutchinson et al., [@B68]), and inevitably causes a prominent global clinical burden (Raimundo et al., [@B134]). For example, a study of medicare population aged 65 years and older showed that the incidence of IPF was around 93.7 cases per 100,000 person-years while the cumulative prevalence increased steadily to 494.5 cases per 100,000 person-years across 2001 to 2011 in US (Raghu et al., [@B133]). Besides, the mortality of non-alcoholic fatty liver disease (NAFLD) patients with a high probability of fibrosis was 69% higher than those without fibrosis (Kim et al., [@B81]).

As a long-lasting pathological phenomenon, fibrosis occurs in various tissues and organs (Figure [1](#F1){ref-type="fig"}), more often in heart, lung, kidney, liver, skin (Rockey et al., [@B139]), and less frequently in other tissues and organs such as pancreas, intestine, eye (Wynn, [@B179]), nerve system (Kawano et al., [@B77]), mediastinum (Parish and Rosenow, [@B128]), retroperitoneum (Caiafa et al., [@B17]), joint and tendon (arthrofibrosis).

![Fibrosis and related diseases in various tissues and organs. Fibrosis is a pathological process that could occur in many tissues and organs and is associated with multiple diseases. Commonly reported fibrosis and associated diseases are listed.](fphar-08-00855-g0001){#F1}

Fibrosis contributes to the development of many diseases. First, many studies have demonstrated that the core mechanisms in fibrosis across various tissues and organs are similar. Wang and colleagues found that the interaction between transforming growth factor-β(TGF-β) and connective tissue growth factor signaling is required in kidney, liver, and lung fibrosis (Wang Q. et al., [@B169]). Makarev and colleagues identified a number of common pathways between lung and liver fibrogenesis, such as TGF-β, interleukin-6(IL-6), and integrin-linked kinase signaling (Makarev et al., [@B109]). Moreover, Wenzke and colleagues detected 90 genes, as well as several networks associated with connective tissue disorders, that play important roles in multi-organ fibrosis including lung, heart, liver, and kidney (Wenzke et al., [@B175]). On the basis of common pathogenesis across fibroproliferative diseases, some new drugs were proved effective in the treatment of fibrosis across different tissues and organs. For example, Pirfenidone has entered into the phase II clinical trial for treating the systemic sclerosis(SSc) (Khanna et al., [@B79]) and the phase III for IPF (King et al., [@B83]), respectively. Interferon drug Actimmune has been evaluated in patients with IPF (Skaria et al., [@B149]), liver (Muir et al., [@B120]), and cystic fibrosis (Moss et al., [@B119]).

Second, in different tissues and organs, multiple fibrotic diseases are related to each other. They are usually triggered by the same irritation and occur simultaneously. For example, heart and kidney together develop fibrosis (cardiorenal fibrosis) owing to the imbalance of natriuretic peptide system pathway and renin angiotensin aldosterone system/TGF-β1 pathway in aging (Sangaralingham et al., [@B143]). Chronic or acute renal failure may induce nephrogenic systemic fibrosis developed from thickening skin (Reiter et al., [@B137]) to impaired internal organs. In addition, cystic fibrosis, caused by gene mutation, could widely affect multiple organs, such as lung, kidney, and pancreas. Moreover, fibrosis is frequently a common pathological process in NAFLD and inflammatory bowel disease. Replacement of heart tissues by fibrotic protein could alter the ventricle size and shape, leading to hypertrophic cardiomyopathy (Khan and Sheppard, [@B78]). Cancers such as hepatocellular carcinoma share a series of risk factors with liver fibrosis (De Minicis et al., [@B33]).

Here we review the current knowledge on the pathological mechanisms of fibrosis and systematically summarize drugs targeting fibrosis in different fibroproliferative diseases. Future directions for fibrosis drug discovery are also proposed.

Pathogenesis of fibrosis {#s2}
========================

Fibrosis is considered as pathological outcomes of normal wound healing (Figure [2](#F2){ref-type="fig"}). When injuries occur and epithelial and/or endothelial cells are damaged, pro-inflammatory cytokines are released by the coagulation cascade for immune cell recruitment, mainly neutrophils and macrophages. These recruited immune cells function as the scavenger to remove tissue debris and dead cells, resulting in acute inflammation. Meanwhile, immune cells themselves release factors like chemokines and cytokines to amplify inflammatory reactions. Next, the released factors, such as TGF-β (Thannickal et al., [@B159]), platelet derived growth factor (PDGF) (Tang et al., [@B157]), interleukin-13 and interleukin-4 (Hashimoto et al., [@B59]), induce the limited activation and proliferation of myofibroblasts. Besides resident fibroblasts, myofibroblasts are derived from multiple cells (Hinz et al., [@B62]), including fibrocytes, epithelial cells via epithelial-mesenchymal transition (EMT), endothelial cells via endothelial-mesenchymal transition, pericytes, and smooth muscle cells related to blood vessels. In liver and pancreas, precursor cells like hepatic stellate cells (HSC) (Moreira, [@B118]) and pancreatic stellate cells (Apte et al., [@B7]) could also acquire myofibroblastic phenotype. Activated myofibroblasts migrate to injury sites, and their abilities to generate cell traction force enable them to stimulate wound closure (Li and Wang, [@B92]). Then, the balance of ECM synthesis and degradation could be achieved by myofibroblasts, resulting in ECM homeostasis. Finally, immune cells undergo apoptosis and epithelial/endothelial cells proliferate to regenerate injury sites, leading to wound healing.

![In normal wound healing condition, there is a series of ordered process: injury, immune cell recruitment and acute inflammation, myfibroblasts limited activation, and proliferation and ECM homeostasis, leading to wound closure after injury. While in pro-fibrotic condition, pathological process including chronic inflammation, myfibroblasts persistent activation, and proliferation and ECM deposition leading to fibrosis. Fibrosis itself could result in a secondary assault. Extracellular and intracellular factors interact with each other. Their abnormalities contribute to the fibrosis progression and in return are affected by pathological changes. Green lines and blocks represent normal wound healing while red lines and blocks represent fibrosis progression.](fphar-08-00855-g0002){#F2}

In contrast to normal wound healing process, the abnormalities of multiple factors could cause fibrosis (Biernacka et al., [@B11]) (Figure [2](#F2){ref-type="fig"}). Under some persistent stimuli, the overexpression of factors like pro-inflammatory cytokines or growth factors would overactivate (Kim et al., [@B82]) and interact with multiple kinases or nuclear receptors. The deficiencies of some factors would also contribute to fibrosis progression (Allen and Spiteri, [@B5]). Then, the abnormal signaling sustains to switch normal wound healing process to pro-fibrotic process, acting on the recruitment of excess immune cells, the induction of the myofibroblasts activation and proliferation and the promotion of ECM production. Pro-fibrotic process also promotes the activation of these factors conversely, thereby amplifying inflammatory responses and causing chronic inflammation. Finally, the sustained myofibroblasts activation would generate masses of ECM and tilt the balance in favor of synthesizing ECM to produce fibrosis. Furthermore, the pro-fibrotic process itself could contribute to secondary injury to the wound and cause a chronic vicious circle of pathological responses.

Below we divide factors modulating fibrosis progression into extracellular and intracellular groups, and discuss how they influence fibrosis progression.

Extracellular factors mediating the progression of fibrosis
-----------------------------------------------------------

The majority of the fibrosis-related extracellular factors are receptor-binding ligands, such as growth factors and cytokines. These factors target adjacent and distant cells in autocrine, paracrine, or endocrine signaling pathways. Then they bind to specific receptors on cell membrane and trigger the intracellular signaling, leading to pro-fibrotic cellular responses. Other extracellular factors, mainly enzymes such as matrix metalloproteinases (MMPs) could degrade ECM to prevent its excessive accumulation.

Growth factors contain a huge family of proteins that stimulate cell growth and proliferation. They are secreted by fibroblasts, immune cells, and epithelial/endothelial cells, and are able to orchestrate cellular responses. While epithelium/endothelium are damaged, cells in these tissues massively upregulate the production of growth factors to promote the proliferation of immune cells and fibroblasts. Among growth factors, TGF-β is the "master" modulator in fibrogensis (Meng et al., [@B115]), as it could provoke fibrosis through SMAD-dependent pathway (Lan, [@B88]) and SMAD-independent pathway related to a number of other pro-fibrotic reactions (Zhang, [@B197]). TGF-β signaling cascade results in differentiation of effector cells via inducing the expression of myofibroblasts hallmark α-hallmar muscle actin(α-SMA) (Sebe et al., [@B145]). In addition, TGF-β signaling leads to the transcription of collagen I and III genes (Fine and Goldstein, [@B47]; Chen et al., [@B23]) contributing to ECM accumulation. Interacting with TGF-β, many other growth factors have distinct roles in pro-fibrotic process. For example, PDGF induces HSC proliferation and type I collagen expression via downstream focal adhesion kinase/phosphoinositide 3-kinase/protein kinase B signaling (Reif et al., [@B136]). On the contrary, some growth factors have anti-fibrotic property, such as hepatocyte growth factor (HGF), the overexpression of which alleviates fibrosis in cardiomyopathic hamster through activation of MMP-1 and urokinase-type plasminogen activator (Taniyama et al., [@B158]). Excessive cytokines are usually secreted by immune cells, such as macrophages, neutrophils, and T cells in inflammation phase of wound healing. Compared with growth factors, cytokines tend to act as cell signaling transmitters to augment immunological responses and then lead to inflammation. One major type of cytokines is chemokines, which guide the recruitment of immune cells and fibroblasts to injury sites. Different immune cells are recruited by different chemokines. Neutrophils could be recruited by chemokine (C-X-C motif) ligand 1 and chemokine (C-X-C motif) ligand 8 by binding glycosaminoglycans with receptors in slightly different ways (Sawant et al., [@B144]). Chemokine (C-C motif) ligand 5 has been a major factor to induce the migration of HSC in liver fibrosis (Seki et al., [@B146]). Another type of cytokines is T cell cytokines, which are mainly secreted by activated T lymphocytes. They include interleukins, interferons and tumor necrosis factors (TNF), mediating adaptive immune responses and inflammation that might promote fibrosis. For example, IL-6 has been reported to shift the tissue repair to a chronic inflammatory state by signal transducer and activator of transcription 3(STAT3) signaling pathway in peritoneal fibrosis (Fielding et al., [@B46]). In contrast, some cytokines have anti-fibrotic effects. It has been reported that interferon-γ down-regulated the Adenosine A2A receptor signaling to prevent the production of type I collagen in HSC (Block and Cronstein, [@B12]). Moreover, some T cell cytokines, such as TNF-α, exhibit two-sided effects, pro-fibrotic or anti-fibrotic effect depending on the alternative status of macrophages and micro-environment (Redente et al., [@B135]).

MMPs are the extracellular endopeptidases degrading ECM including collagens, proteoglycans, laminins, and fibronectin. Tissue inhibitor of metalloproteinases (TIMPs) work as the inhibitors of MMPs. The balance of MMPs and TIMPs modulates the process throughout fibrosis development, including the formation of multiple cell injuries, the activation of latent cytokines and myofibroblasts and mainly, the maintenance of the homeostasis of ECM (Giannandrea and Parks, [@B53]). Some MMPs have pro-fibrotic functions whereas some have anti-fibrotic according to cell types and phases. The dysregulation of MMP-19 has been proved to cause the degradation of normal liver ECM and initiate liver injury (Jirouskova et al., [@B74]). Conversely, MMP-2 has been reported to cleave type I collagen and attenuate collagen deposition by HSC, inhibiting liver fibrosis (Radbill et al., [@B131]). As to TIMPs, they could inhibit or activate fibrosis via MMPs. For example, TIMP-3 inhibits MMPs to induce inflammation (Gill et al., [@B54]) in lung injury, and TIMP-1 has been found to play a dual role in liver fibrosis (Wang H. et al., [@B168]).

Other extracellular factors include a wide range of proteins and peptides. They mainly guide the differentiation of myofibroblasts, and are closely related to each other and growth factors. For example, the hedgehog (Hh) signaling pathway mediates EMT during the fetal development, and responds to injury through the repression of epithelial marker epithelial-cadherin by *Snail* and *Twist*. Overactivation of Hh signaling pathway contributes to biliary fibrosis and related liver fibrosis (Omenetti et al., [@B124]). In fibrotic kidney, the upregulated Wnt signaling has been reported to result in abundant of β-catenin. The signaling regulates genes such as *Twist, LEF1* to induce EMT, thus to aggravate disease (He et al., [@B60]).

Intracellular factors mediating the progression of fibrosis
-----------------------------------------------------------

Intracellular factors, mainly multiple kinases, propagate the signaling received by cells through phosphorylation and other pathways. A common consequence of the signaling is that, transcription activators or inhibitors translocate into nucleus to regulate fibrosis-related gene expression and cell responses. In certain inflammatory pathways, intracellular factors also modulate the expression of extracellular factors, such as growth factors and cytokines, and secrete them out of cells to amplify inflammatory responses. Besides, epigenetic factors are emerging as a new way to affect fibrosis-related gene expression.

Intracellular factors include a number of kinases. In inflammation phase, many upstream factors, such as TGF-β, TNF-α, and epidermal growth factors initiate mitogen-activated protein kinase (MAPK) pathway. An element of MAPK pathway, mitogen-activated protein kinase-activated protein kinase-2 mediates myofibroblasts differentiation and regulates the gene expression of several matrix proteins such as *col1a2, col3a1*, and *lox* (Vittal et al., [@B167]). Another important intracellular signaling, mechanistic target of rapamycin (mTOR) pathway is activated by Wnt and TNF-α. Then, mTOR pathway activates ribosomal protein S6 kinase β-1 and modulates protein p21 or p27, which regulates the cell cycle of many cells including fibroblasts. In addition, the inhibition of mTOR pathway reduces collagen deposition and cardiac fibrosis (Chen et al., [@B22]). Besides serving as amplifiers of signal transduction, some intracellular enzymes such as cathepsin K, which belongs to lysosomal cysteine proteases, have been proved to be able to degrade ECM in lysosome after phagocytosis (Fukumori et al., [@B49]; Buhling et al., [@B15]).

Nuclear receptors are receptors located in cytoplasm and nucleus that could receive signals from intracellular ligands and bind to DNA to regulate gene expression. For example, peroxisome proliferator activated receptor γ(PPAR-γ), may directly regulate type I collagen gene (Yang et al., [@B185]) and block TGF-β signaling (Ghosh et al., [@B52]). Another nuclear receptor, farnesoid-X receptor (FXR), exhibits anti-fibrotic effect via the reduction of proliferating cholangiocytes and subsequent reduction of TGF-β (Liu et al., [@B105]). The activation of FXR also decreases a series of pro-fibrotic factors including TIMP-1, collagens, α-SMA, and MMP-2 (Zhang et al., [@B193]).

Nowadays, epigenetics including microRNAs, DNA methylation and lncRNAs, are found involved in machinery of pro-fibrotic process mainly through regulating fibrosis-related gene expression. Some microRNAs are found to negatively regulate translation of ECM components. Among them, miR-21 induces extracellular-signal regulated kinase/MAPK activity via the inhibition of *Spry1* to protect cardiac fibroblasts survival (Thum et al., [@B160]). It has been reported that the levels of DNA methylation at specific CpG sites of pro-fibrotic genes (*PPAR*α*, PPAR*δ*, TGF*β*1, Collagen1A1*, and *PDGF*α) differ among different fibrosis stages in NAFLD (Zeybel et al., [@B189]).

There are factors that affect fibrosis process both extra- and intracellularly, including reactive oxygen species (ROS), galectin-3 and lysyl oxidase homolog 2 (LOXL2). ROS can be generated through tissue injuries, cell damages and NADPH oxidase activities. Extracellular ROS targets latency-associated peptides and then activates TGF-β signaling while intracellular oxidative stress induces p53-dependent apoptosis in lung fibrosis via the caspases-9/3 activation in mitochondria (Cheresh et al., [@B25]). As to galectin-3, extracellular galectin-3 induces T cell apoptosis and plays a dual function inside and outside cells (Li et al., [@B96]). Another factor LOXL2 is generally considered as extracellular enzyme that promotes collagen production and crosslink with collagen fibers in response to mechanical stress (Yang et al., [@B184]). While on the other hand, intracellular LOXL2 has been reported to induce EMT in carcinoma progression (Peinado et al., [@B129]).

Many studies proved that different fibroproliferative diseases share common underlying mechanisms (Wenzke et al., [@B175]). The existence of common mechanisms facilitates the complete interpretation of fibrosis pathogenesis and enhances our understanding of fibrosis-related diseases. On this basis, it is necessary to reconsider targets involved in these mechanisms and evaluate their potential roles in fibrosis treatment across tissues and organs.

Drugs and targets in fibrosis {#s3}
=============================

Motivated by huge clinical burdens, continuous intense researches on drug targeting fibrosis have been conducted, many of which have led to clinical trials. Due to the strong associations between inflammation and fibrosis, more efforts have been devoted to anti-inflammation drugs in the past few years (Dinwiddie, [@B38]). Nowadays, new targets and drugs for fibrosis are constantly emerging with the progress in understanding fibrosis pathology. Here we summarize them in Tables [1](#T1){ref-type="table"}--**4**, including single (Tables [1](#T1){ref-type="table"}--**3**) and multi component (**Table 4**) drugs with their verified and potential targets in fibrosis.

###### 

Single-component drugs targeting extracellular factors.

  **Target**                                                                 **Drug**                                                                    **Clinical trial**[^b^](#TN3){ref-type="table-fn"}   **Reference**                                                                                                                                                                                                                            
  -------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ------------ --------------------- ------------------------------------------ ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Growth factors                                                             Extracellular TGF-β signaling                                               TGF-β[^d^](#TN5){ref-type="table-fn"}                Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   SHP-627 (FT011)                                    Inhibitor    Small molecule        Cardiac fibrosis                           Preclinical                                           Zhang et al., [@B198]
                                                                                                                                                                                                                                                                Hydronidone (F351)                                 Inhibitor    Small molecule        Liver fibrosis                             2(unknown)                                            NCT02499562
                                                                                                                                                                                                                                                                PXS-25                                             Inhibitor    Small molecule        IPF[^d^](#TN5){ref-type="table-fn"}        Preclinical                                           Maldonado et al., [@B110]; Wong et al., [@B178]
                                                                                                                                                                                                                                                                Disitertide (P-144)                                Inhibitor    Small molecule        Skin fibrosis                              2(completed)                                          NCT00574613
                                                                                                                                                                                                                                                                Fresolimumab (GC-1008)                             Inhibitor    Monoclonal antibody   IPF; SSc[^d^](#TN5){ref-type="table-fn"}   1(completed); 1(completed)                            NCT00125385; NCT01284322
                                                                                                                                                                                                                                                                LY2382770                                          Inhibitor    Monoclonal antibody   Diabetic kidney disease                    2(terminated)                                         NCT01113801
                                                                                                                                                         Integrin αvβ6                                                                                          STX-100                                            Inhibitor    Monoclonal antibody   IPF                                        2(completed)                                          NCT01371305
                                                                                                                                                                                                                                                                CWHM-12                                            Inhibitor    Small molecule        Liver fibrosis; Lung fibrosis              Preclinical                                           Henderson et al., [@B61]
                                                                                                                                                         ALK5[^d^](#TN5){ref-type="table-fn"}                                                                   SB-431542                                          Antagonist   Small molecule        Pulmonary fibrosis                         Preclinical                                           Koh et al., [@B85]
                                                                                                                                                         BMP-7[^d^](#TN5){ref-type="table-fn"}                                                                  THR-184                                            Agonist      Small molecule        Renal fibrosis                             2(completed)                                          NCT01830920
                                                                             CTGF[^d^](#TN5){ref-type="table-fn"}                                        CTGF                                                                                                   PF-06473871                                        Inhibitor    Small molecule        Hypertrophic scar                          2(completed)                                          NCT01730339
                                                                                                                                                                                                                                                                RXI-109                                            Inhibitor    Small molecule        Hypertrophic scar                          2(completed)                                          NCT02030275
                                                                                                                                                                                                                                                                FG-3019                                            Inhibitor    Monoclonal antibody   IPF                                        2(active, not recruiting)                             NCT01890265
                                                                             PDGF[^d^](#TN5){ref-type="table-fn"}/VEGF[^d^](#TN5){ref-type="table-fn"}   PDGFR[^d^](#TN5){ref-type="table-fn"}                                                                  Imatinib                                           Antagonist   Small molecule        Nephrogenic systemic fibrosis; SSc; IPF    Approved\| 2(completed); 2(completed); 3(completed)   NCT00677092; NCT00613171; NCT00131274
                                                                                                                                                                                                                                                                BOT-191                                            Antagonist   Small molecule        Liver fibrosis                             Preclinical                                           van Dijk et al., [@B164]
                                                                                                                                                                                                                                                                Nilotinib (AMN-107)                                Antagonist   Small molecule        SSc                                        Approved\| 2(completed)                               NCT01166139
                                                                                                                                                                                                                                                                Dasatinib                                          Antagonist   Small molecule        Scleroderma pulmonary fibrosis             Approved\| 2(completed)                               NCT00764309
                                                                                                                                                         VEGFR[^d^](#TN5){ref-type="table-fn"}/PDGFR                                                            Nintedanib (BIBF-1120)                             Antagonist   Small molecule        Scleroderma; IPF                           Approved\| 3(recruiting); 3(completed)                NCT02597933; NCT01335464
                                                                                                                                                                                                                                                                Sorafenib (BAY 43-9006)                            Antagonist   Small molecule        Extensive keloids                          Approved\| 2(terminated)                              NCT01425216
                                                                             TNF[^d^](#TN5){ref-type="table-fn"}                                         TNF                                                                                                    Thalidomide                                        Inhibitor    Small molecule        IPF                                        Approved\| 2(completed)                               NCT00162760
                                                                                                                                                                                                                                                                Pomalidomide                                       Inhibitor    Small molecule        IPF                                        Approved\| 2(withdrawn)                               NCT01135199
                                                                                                                                                                                                                                                                Etanercept                                         Inhibitor    Recombinant protein   IPF                                        Approved\| 2(completed)                               NCT00063869
                                                                                                                                                                                                                                                                Belimumab                                          Inhibitor    Monoclonal antibody   SSc                                        Approved\| 2(completed)                               NCT01670565
                                                                             HGF[^d^](#TN5){ref-type="table-fn"}                                         HGF                                                  Liver, Kidney, Lung, Heart, Skin                  Refanalin (BB-3)                                   Stimulant    Small molecule        Liver fibrosis; IPF                        Preclinical                                           Fallowfield, [@B41]
  Cytokines                                                                  Interleukin                                                                 IL-13[^d^](#TN5){ref-type="table-fn"}                Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   Dectrekumab (QAX-576)                              Inhibitor    Monoclonal antibody   IPF; IPF secondary to SSc                  2(terminated); 2(terminated)                          NCT01266135; NCT00581997
                                                                                                                                                                                                                                                                Tralokinumab                                       Inhibitor    Monoclonal antibody   IPF                                        2(terminated)                                         NCT01629667
                                                                                                                                                         IL-1R1                                               Liver, Kidney, Lung, Heart, Skin, Gut             Anakinra                                           Antagonist   Recombinant protein   Cystic fibrosis                            Approved\| Preclinical                                Iannitti et al., [@B70]
                                                                                                                                                         IL-1βR                                                                                                 Rilonacept                                         Antagonist   Recombinant protein   SSc                                        Approved\| 2(active, not recruiting)                  NCT01538719
                                                                                                                                                         IL-13/IL-4                                                                                             SAR156597                                          Inhibitor    Monoclonal antibody   SSc; IPF                                   2(recruiting); 2(completed)                           NCT02921971; NCT01529853
                                                                             CC chemokine                                                                CCL2[^d^](#TN5){ref-type="table-fn"}                 Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   Carlumab (CNTO-888)                                Inhibitor    Monoclonal antibody   IPF                                        2(completed)                                          NCT00786201
                                                                                                                                                                                                                                                                Bindarit                                           Inhibitor    Small molecule        Myocardial fibrosis; Renal fibrosis        Preclinical                                           Lin et al., [@B97]; Zhu et al., [@B206]
                                                                                                                                                         CCR5[^d^](#TN5){ref-type="table-fn"}                 Liver, Kidney, Lung                               Maraviroc                                          Antagonist   Small molecule        Liver fibrosis                             Approved\| Preclinical                                Gonzalez et al., [@B56]
                                                                                                                                                         CCR2                                                 Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   RS-504393                                          Antagonist   Small molecule        Renal fibrosis                             Preclinical                                           Kitagawa et al., [@B84]
                                                                             Interferon                                                                  IFN-γR[^d^](#TN5){ref-type="table-fn"}                                                                 Actimmune                                          Stimulant    Interferon            IPF; Liver fibrosis; Cystic fibrosis       Approved\| 3(completed); 2(completed); 2(completed)   NCT00047658; NCT00043303; NCT00043316
                                                                                                                                                         IFN-α                                                Liver, Kidney, Lung                               Interferon alpha oral lozenge                      Stimulant    Interferon            Pulmonary fibrosis                         2(completed)                                          NCT01442779
  MMP[^d^](#TN5){ref-type="table-fn"}/TIMP[^d^](#TN5){ref-type="table-fn"}   MMP/TIMP                                                                    MMP-2/MMP-9/TIMP-1                                   Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   Batimastat(BB-49)                                  Inhibitor    Small molecule        IPF                                        Preclinical                                           Corbel et al., [@B28]
                                                                                                                                                         MMP/TIMP                                                                                               Marimastat                                         Inhibitor    Small molecule        Liver fibrosis                             Approved\| Preclinical                                de Meijer et al., [@B32]
  Other proteins and peptides                                                Endothelin                                                                  ET-1 receptor[^d^](#TN5){ref-type="table-fn"}        Liver, Kidney, Lung, Heart, Skin, Gut             Macitentan                                         Antagonist   Small molecule        IPF                                        Approved\| 2(completed)                               NCT00903331
                                                                                                                                                                                                                                                                Bosentan                                           Antagonist   Small molecule        IPF; SSc;                                  Approved\| 3(completed); 3(completed); 4(completed)   NCT00070590; NCT00319696; NCT01395732
                                                                                                                                                                                                                                                                Ambrisentan                                        Antagonist   Small molecule        IPF; SSc                                   Approved\| 3(terminated); 4(unknown)                  NCT00879229; NCT01051960
                                                                                                                                                                                                                                                                Sparsentan (RE-021)                                Antagonist   Small molecule        Focal segmental glomerulosclerosis         2(active, not recruiting)                             NCT01613118
                                                                                                                                                                                                                                                                Atrasentan                                         Antagonist   Small molecule        Renal fibrosis                             Preclinical                                           Samad et al., [@B141]
                                                                             Angiotensin II                                                              AT1 receptor[^d^](#TN5){ref-type="table-fn"}         Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   Losartan                                           Antagonist   Small molecule        Liver fibrosis; Cystic fibrosis            Approved\| 4(completed); 2(not yet recruiting)        NCT00298714; NCT03206788
                                                                             GPCR[^d^](#TN5){ref-type="table-fn"}                                        LPAR[^d^](#TN5){ref-type="table-fn"}                 Liver, Kidney, Lung, Skin                         BMS-986020                                         Antagonist   Small molecule        SSc; IPF                                   2(withdrawn); 2(completed)                            NCT02588625; NCT01766817
                                                                                                                                                                                                                                                                SAR-100842                                         Antagonist   Small molecule        SSc                                        2(completed)                                          NCT01651143
                                                                                                                                                         PAR1[^d^](#TN5){ref-type="table-fn"}                 Liver, Kidney, Lung, Heart, Pancreas, Skin        PAR1 antagonism                                    Antagonist   Small molecule        Liver fibrosis                             Preclinical                                           Fiorucci et al., [@B48]
                                                                                                                                                         CB1 receptor[^d^](#TN5){ref-type="table-fn"}         Liver                                             Curcumin[^\*^](#TN1){ref-type="table-fn"}          Antagonist   Small molecule        Liver fibrosis; Renal fibrosis; IPF        Preclinical                                           Smith et al., [@B150]; Zhang et al., [@B199]; Sun et al., [@B152]
                                                                                                                                                                                                                                                                Silymarin[^\*^](#TN1){ref-type="table-fn"}         Antagonist   Small molecule        Liver fibrosis                             Preclinical                                           Tsai et al., [@B162]; Zhang et al., [@B199]
                                                                                                                                                         CB2 receptor[^d^](#TN5){ref-type="table-fn"}                                                           β-caryophyllene[^\*^](#TN1){ref-type="table-fn"}   Agonist      Small molecule        Liver fibrosis                             Preclinical                                           Calleja et al., [@B18]; Mahmoud et al., [@B108]
                                                                                                                                                         Prostacyclin receptor                                Liver, Kidney, Lung, Heart, Pancreas              Beraprost                                          Agonist      Small molecule        Renal fibrosis; Cardiac fibrosis           Preclinical                                           Chen et al., [@B24]
                                                                                                                                                                                                                                                                Iloprost                                           Agonist      Small molecule        SSc                                        Approved\| 2(completed)                               NCT00109681
                                                                                                                                                                                                                                                                Treprostinil                                       Agonist      Small molecule        IPF; SSc                                   Approved\| 2(terminated); 2(completed)                NCT00703339; NCT00775463
                                                                                                                                                         VIP receptor                                         Lung                                              Aviptadil                                          Agonist      Peptide hormone       Cystic fibrosis                            Preclinical                                           Mathioudakis et al., [@B113]
                                                                             Leukocyte elastase                                                          Leukocyte elastase                                                                                     Sivelestat                                         Inhibitor    Small molecule        IPF                                        Preclinical                                           Takemasa et al., [@B155]
                                                                             TAFI[^d^](#TN5){ref-type="table-fn"}                                        TAFI                                                 Liver, Kidney, Lung                               UK-396082                                          Inhibitor    Small molecule        Renal fibrosis                             Preclinical                                           Atkinson et al., [@B8]
                                                                             Relaxin                                                                     Relaxin receptor                                     Liver, Kidney, Lung, Heart, Skin                  Serelaxin                                          Stimulant    Peptide hormone       Cardiac fibrosis; Renal fibrosis           Preclinical                                           Samuel et al., [@B142]; Huuskes et al., [@B69]
                                                                             SAP[^d^](#TN5){ref-type="table-fn"}                                         SAP (mimic)                                                                                            PRM-151                                            Stimulant    Recombinant protein   IPF                                        2(active, not recruiting)                             NCT02550873
                                                                             Integrin α                                                                  Integrin α5                                          Liver                                             Dioscin[^\*^](#TN1){ref-type="table-fn"}           Inhibitor    Small molecule        Liver fibrosis                             Preclinical                                           Liu et al., [@B101]; Zhang et al., [@B194],[@B195]; Gu et al., [@B57]; Xu et al., [@B181]; Yin et al., [@B188]
                                                                             TGM[^d^](#TN5){ref-type="table-fn"}                                         TGM2                                                 Kidney, Lung                                      NTU281                                             Inhibitor    Small molecule        Renal fibrosis                             Preclinical                                           Johnson et al., [@B75]

*Drug belongs to monomer extracted from natural products*.

*Organs that had study report of corresponding targets in fibrosis treatment*.

*Clinical trial resource are from <http://Clinicaltrials.gov>*.

Trial Identifier is the clinical trail identifier of corresponding drug

*TGF-β, transforming growth factor-β; IPF, idiopathic pulmonary fibrosis; SSc, systematic sclerosis; ALK5, TGF-β receptor 1; BMP-7, bone morphogenetic protein 7; CTGF, connective tissue growth factor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; TNF, tumor necrosis factor; HGF, hepatocyte growth factor; IL-13, interleukin-13; CCL2, chemokine (C-C motif) ligand 2; CCR5, C-C chemokine receptor type 5; IFN-γR, interferon-γ receptor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; ET-1 receptor, endothelin-1 receptor; AT1 receptor, angiotensin II receptor type 1; GPCR, G protein-coupled receptor; LPAR, lysophosphatidic acid receptor; PAR1, protease-activated receptor 1; CB1 receptor, cannabinoid receptor type 1; TAFI, thrombin activatable fibrinolysis inhibitor; SAP, serum amyloid P; VIP, vasoactive intestinal peptide; TGM2, transglutaminase*.

Single-component drugs targeting extracellular factors mediating fibrosis
-------------------------------------------------------------------------

Nowadays, most approved and investigational drugs are single-component drugs, which only contain one organic component and have distinct targets. As we described previously, fibrosis progression results from a combination of the abnormalities of extracellular and intracellular factors. Drugs targeting extracellular factors are prevalent, about 60% of known targets are receptors located on cell membrane mainly because the extracellular targets are accessible and serve as upstream signals (Overington et al., [@B126]), and so are the targets of fibrosis-related drugs. The binding of receptors and ligands triggers the downstream signaling, thus the blockade of receptors or ligands is considered to be an effective choice to alleviate fibrosis (Table [1](#T1){ref-type="table"}).

The majority of anti-fibrosis drugs targeting extracellular factors are inhibitors of ligands such as growth factors, cytokines and MMPs. Most inhibitors could directly bind to the active sites of targets. The majority of approved inhibitor drugs in Table [1](#T1){ref-type="table"} target TNF, which are widely used in fibrosis-related diseases and could suppress the action of TNF through multiple mechanisms. These drugs include small molecules Thalidomide and Pomalidomide (Weingartner et al., [@B174]), recombinant protein Etanercept and monoclonal antibodies Belimumab. Thalidomide and Etanercept have completed the phase II trial in IPF (Raghu et al., [@B132]; Horton et al., [@B64]) while Belimumab has completed the phase II trial in SSc. Besides, some inhibitor drugs targeting growth factors are still under investigation. For example, Disitertide, a synthetic peptide derived from TGF-β type III receptor, inhibits the binding of TGF-β and its receptor and exhibit anti-fibrotic function (Ezquerro et al., [@B40]). Drugs that inhibit interleukins are always monoclonal antibodies. Tralokinumab, a human IgG4 monoclonal antibody, shows pro-apoptotic effects via IL-induced apoptotic factors in IPF (Murray et al., [@B121]). Many natural products act as inhibitor drugs like Dioscin, which is a monomer extracted from *Dioscoreae Rhizoma* and could ameliorate liver fibrosis (Liu et al., [@B101]; Zhang et al., [@B194],[@B195]; Gu et al., [@B57]; Xu et al., [@B181]; Yin et al., [@B188]). In addition, some preclinical drugs inhibit MMPs, like Marimastat, which simultaneously down-regulates MMPs gene expression and MMPs activities. However, Marimastat reduces inflammation and liver injuries while increases fibrosis in mice model. This may result from the indiscriminative inhibition of MMPs, some of which function to degrade ECM (de Meijer et al., [@B32]).

Compared with inhibitor drugs, antagonists achieve the same inhibition effect by targeting cell membrane receptors to dampen downstream signaling. These small molecules bind to receptors without effectively activating them. The receptors of PDGF, vascular endothelial growth factor, endothelin (ET), and angiotensin all have approved antagonist drugs. An antagonist for tyrosine kinase receptors of PDGF, Imatinib, has showed protective effect by reducing differentiation of resting fibroblasts in SSc mice model (Akhmetshina et al., [@B1]). However, it did not show efficacy in phase II clinical trial in IPF (Daniels et al., [@B31]) and the high-dose of Imatinib may lead to severe adverse events (Khanna et al., [@B80]). Macitentan, a dual antagonist of ET~A~ and ET~B~ receptor, is beneficial for lung fibrosis. Similarly, another drug Losartan targeting angiotensin II receptor has been evaluated in IPF patients (Couluris et al., [@B29]). Some preclinical antagonist drugs including Maraviroc (Gonzalez et al., [@B56]), Atrasentan (Ritter et al., [@B138]), and PAR1 antagonists (Fiorucci et al., [@B48]) were under investigation for fibrosis treatment.

On the contrary, many drugs exert their therapeutic effects by activating their targets. Many anti-fibrotic receptors can be targets of these exogenous agonists that augment the downstream biological responses to suppress fibrosis. An approved agonist drug in this category is Iloprost, which can reverse right ventricle fibrosis by re-establishing collagen balance (Gomez-Arroyo et al., [@B55]). Another agonist of vasoactive intestinal peptide, Treprostinil, reduces inflammation and collagen deposition (Manitsopoulos et al., [@B111]). Other anti-fibrotic agonists for cell membrane receptors include Aviptadil, INT-767 (Baghdasaryan et al., [@B9]) and Beraprost (Kaneshige et al., [@B76]).

Moreover, a few drugs are synthetic proteins that bind receptors to serve as stimulants and perform the same functions as native proteins. An approved drug, synthetic interferon-γ, Actimmune, has completed phase II or phase III study in multiple fibrosis including IPF (Skaria et al., [@B149]), liver fibrosis (Muir et al., [@B120]), and cystic fibrosis (Moss et al., [@B119]). Another stimulant Refanalin, a HGF mimetic, is a potential drug for liver fibrosis (Fallowfield, [@B41]; Pellicoro et al., [@B130]).

Single-component drugs targeting intracellular factors mediating fibrosis
-------------------------------------------------------------------------

Compared with extracellular factors, intracellular targets are less popular owing to their inaccessibility. Drugs targeting intracellular factors are less varied because most of them are small molecules. Small molecules could readily translocate into cytoplasm while large molecules such as monoclonal antibodies face more challenges to cross the plasma membrane (Imai and Takaoka, [@B71]). Nevertheless, more and more studies concerned intracellular factors as targets in recent years, and numerous candidate targets are identified in cytoplasm, nucleus, and mitochondrion. Many approaches, including increasing membrane permeation, combination with supercharged proteins and activating transport through receptors, were implemented to deliver drugs across cell membrane (Mitragotri et al., [@B117]).

Fibrosis drugs targeting intracellular factors are summarized and classified into four categories: enzymes, nuclear receptors, other proteins, and epigenetics (Table [2](#T2){ref-type="table"}). Many drugs acting through intracellular factors are also inhibitors. These drugs inhibit a wide range of kinases located in cytoplasm, and consequently suppress the translocation of transcription factors that drive the expression of pro-fibrotic genes. Rapamycin and Sirolimus are approved drugs that inhibit mTOR. Rapamycin prevents the activation of macrophages and myofibroblasts and the subsequent release of TGF-β in chronic kidney disease (CKD) (Chen et al., [@B22]). Sirolimus shows anti-inflammatory and anti-fibrotic effects in IPF (Tulek et al., [@B163]). Besides kinases, there are many other intracellular proteins that serve as potential targets for fibrosis management. Pirfenidone, one of the IPF drugs, has completed phase III trial in IPF patients with alleviated disease progression and acceptable side effects (King et al., [@B83]). The potential mechanism of Pirfenidone is inhibiting the nuclear accumulation of intracellular proteins SMAD2/3 to regulate TGF-β signaling (Choi et al., [@B27]). Other approved inhibitor drugs include Ruxolitinib for bone marrow fibrosis (Wilkins et al., [@B176]), Paquinimod for SSc (Stenstrom et al., [@B151]), and Pentoxifylline (Okunieff et al., [@B123]) combined with vitamin E (Jacobson et al., [@B72]).

###### 

Single-component drugs targeting intracellular factors.

  **Target**          **Drug**                                                         **Clinical trial**[^b^](#TN8){ref-type="table-fn"}   **Reference**                                                                                                                                                                                                                                               
  ------------------- ---------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------- ----------- --------------------------- ----------------------------------------------------------- --------------------------------------- ----------------------------------------------------------------------
  Enzymes             mTOR[^d^](#TN10){ref-type="table-fn"}                            mTORC1/2[^d^](#TN10){ref-type="table-fn"}            Liver, Kidney, Lung, Heart, Skin, Gut             Rapamycin (Sirolimus)[^\*^](#TN6){ref-type="table-fn"}        Inhibitor   Small molecule              Renal interstitial fibrosis                                 Approved\| 3(completed)                 NCT01079143
                                                                                                                                                                                              Palomid-529 (RES-529)                                         Inhibitor   Small molecule              Macular degeneration                                        1(completed)                            NCT01033721
                      JAK-STAT[^d^](#TN10){ref-type="table-fn"}                        JAK1/JAK2[^d^](#TN10){ref-type="table-fn"}                                                             Ruxolitinib                                                   Inhibitor   Small molecule              Myelofibrosis                                               Approved\| 3(completed)                 NCT00952289
                                                                                                                                                                                              Baricitinib                                                   Inhibitor   Small molecule              Renal interstitial fibrosis                                 Preclinical                             Breyer and Susztak, [@B14]
                      PI3K-Akt[^d^](#TN10){ref-type="table-fn"}                        Akt                                                  Liver, Kidney, Lung, Heart, Skin                  Omipalisib (GSK2126458)                                       Inhibitor   Small molecule              IPF[^d^](#TN10){ref-type="table-fn"}                        1(completed)                            NCT01725139
                                                                                       FAK1[^d^](#TN10){ref-type="table-fn"}                Liver, Kidney, Lung, Heart, Pancreas, Skin        PF-562271                                                     Inhibitor   Small molecule              Pulmonary fibrosis; Cardiac fibrosis; Liver fibrosis        Preclinical                             Lagares et al., [@B87]; Fan et al., [@B42]; Zhao et al., [@B201]
                      MAPK[^d^](#TN10){ref-type="table-fn"}                            JNK[^d^](#TN10){ref-type="table-fn"}                                                                   Tanzisertib (CC-930)                                          Inhibitor   Small molecule              IPF                                                         2(terminated)                           NCT01203943
                                                                                       MAPK                                                 Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   MMI-0100                                                      Inhibitor   Small molecule              IPF; Cardiac fibrosis                                       Preclinical                             Xu et al., [@B180]
                      NF-κB[^d^](#TN10){ref-type="table-fn"}                           IKK[^d^](#TN10){ref-type="table-fn"}                                                                   IMD-1041                                                      Inhibitor   Small molecule              Cardiac fibrosis                                            Preclinical                             Tanaka et al., [@B156]
                                                                                                                                                                                              Bardoxolone methyl (CDDO-Me)                                  Inhibitor   Small molecule              Pulmonary hypertension                                      2(recruiting)                           NCT02036970
                                                                                       NF-κB                                                                                                  Antisense NF-κB                                               Inhibitor   Antisense oligonucleotide   Intestinal fibrosis                                         Preclinical                             Lawrance et al., [@B89]
                                                                                                                                                                                              Baicalein[^\*^](#TN6){ref-type="table-fn"}                    Inhibitor   Small molecule              Renal fibrosis; IPF                                         Preclinical                             Gao et al., [@B50]; Wang et al., [@B170]
                                                                                                                                                                                              Sulfasalazine                                                 Inhibitor   Small molecule              Liver fibrosis; Pancreatic fibrosis                         Approved\| Preclinical                  Chavez et al., [@B20]; Wang et al., [@B171]
                      cAMP-PKA[^d^](#TN10){ref-type="table-fn"}                        ROCK[^d^](#TN10){ref-type="table-fn"}                                                                  Y-27632                                                       Inhibitor   Small molecule              Renal fibrosis; Liver fibrosis                              Preclinical                             Tada et al., [@B153]
                      Non-kinase enzyme                                                26S protease                                         Liver, Kidney, Lung, Heart                        Bortezomib                                                    Inhibitor   Small molecule              SSc pulmonary fibrosis                                      Approved\| 2(recruiting)                NCT02370693
                                                                                       Caspase                                              Liver, Kidney, Lung, Heart, Skin                  Emricasan                                                     Inhibitor   Small molecule              Liver fibrosis                                              Preclinical                             Barreyro et al., [@B10]
                                                                                                                                                                                              VX-166                                                        Inhibitor   Small molecule              Liver fibrosis                                              Preclinical                             Witek et al., [@B177]
                                                                                                                                                                                              Z-VAD-fmk                                                     Inhibitor   Small molecule              Pulmonary fibrosis                                          Preclinical                             Kuwano et al., [@B86]
                                                                                       PDE[^d^](#TN10){ref-type="table-fn"}                 Kidney, Heart                                     CTP-499                                                       Inhibitor   Small molecule              Diabetic nephropathy                                        1(completed)                            NCT01328821
                                                                                       Cathepsin B                                          Liver, Lung, Heart, Pancreas                      VBY-376                                                       Inhibitor   Small molecule              Liver fibrosis                                              Preclinical                             Alkhouri et al., [@B4]
                                                                                                                                                                                              CA-074Me                                                      Inhibitor   Small molecule              Pancreatic fibrosis; Cardiac fibrosis; Pulmonary fibrosis   Preclinical                             Lerch and Halangk, [@B91]; Liu et al., [@B98]; Zhang et al., [@B191]
                                                                                       S100A9                                               Liver, Lung, Heart, Skin                          Paquinimod                                                    Inhibitor   Small molecule              SSc[^d^](#TN10){ref-type="table-fn"}                        2(completed)                            NCT01487551
                                                                                       Procollagen-proline dioxygenase                      Liver, Lung                                       HOE-077                                                       Inhibitor   Small molecule              Liver fibrosis                                              Preclinical                             Matsumura et al., [@B114]
  Nuclear receptors   PPAR[^d^](#TN10){ref-type="table-fn"}                            PPAR-γ                                               Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   Rosiglitazone                                                 Agonist     Small molecule              Liver fibrosis;                                             Approved\| 2(completed)                 NCT00492700
                                                                                                                                                                                              Elafibranor (GFT-505)                                         Agonist     Small molecule              Liver fibrosis                                              3(recruiting)                           NCT02704403
                                                                                                                                                                                              Saroglitazar                                                  Agonist     Small molecule              Liver fibrosis                                              2(recruiting)                           NCT03061721
                                                                                                                                                                                              Pioglitazone                                                  Agonist     Small molecule              Cystic fibrosis; Liver fibrosis                             Approved\| 1(completed); 1(completed)   NCT00719381; NCT01454336
                                                                                                                                                                                              Docosahexaenoic acid[^\*^](#TN6){ref-type="table-fn"}         Agonist     Small molecule              Liver fibrosis; Pulmonary fibrosis                          Preclinical                             Depner et al., [@B36]; Zhao et al., [@B200]
                      FXR[^d^](#TN10){ref-type="table-fn"}                             FXR                                                  Liver, Kidney, Lung, Gut                          INT-767                                                       Agonist     Small molecule              Liver fibrosis                                              Preclinical                             Baghdasaryan et al., [@B9]
                                                                                                                                                                                              PX-102                                                        Agonist     Small molecule              Liver fibrosis                                              Preclinical                             Ali et al., [@B3]
                                                                                                                                                                                              Obeticholic acid[^\*^](#TN6){ref-type="table-fn"} (INT-747)   Agonist     Small molecule              Liver fibrosis                                              Approved\| 3(recruiting)                NCT02548351
                                                                                                                                                                                              Turofexorate isopropyl (WAY-362450)                           Agonist     Small molecule              Liver fibrosis                                              Preclinical                             Zhang et al., [@B193]
                                                                                                                                                                                              GW4064                                                        Agonist     Small molecule              Liver fibrosis                                              Preclinical                             Liu et al., [@B105]
                      GR[^d^](#TN10){ref-type="table-fn"}                              GR                                                   Liver, Lung, Heart, Skin                          Triamcinolone                                                 Agonist     Small molecule              Keloid scarring                                             Approved\| 1(terminated)                NCT01978301
                      ER[^d^](#TN10){ref-type="table-fn"}                              ERβ                                                  Liver                                             Genistein[^\*^](#TN6){ref-type="table-fn"}                    Agonist     Small molecule              Pulmonary fibrosis; Liver fibrosis                          Preclinical                             Salas et al., [@B140]; Nadadur et al., [@B122]
  Other proteins      Intracellular TGF-β[^d^](#TN10){ref-type="table-fn"} signaling   SMAD2/3                                              Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut   Pirfenidone                                                   Inhibitor   Small molecule              IPF; SSc                                                    Approved\| 3(completed); 2(completed)   NCT00287729; NCT01933334
                                                                                       SMAD3/4                                                                                                Pentoxifylline                                                Inhibitor   Small molecule              Skin fibrosis                                               Approved\| 2(completed)                 NCT00001437
                                                                                       SMAD3                                                                                                  SIS-3                                                         Inhibitor   Small molecule              Renal fibrosis                                              Preclinical                             Meng et al., [@B116]
                                                                                                                                                                                              Glycyrrhizin[^\*^](#TN6){ref-type="table-fn"}                 Inhibitor   Small molecule              Liver fibrosis                                              3(terminated)                           NCT00686881
  Epigenetics         miRNA                                                            miR-21                                                                                                 Anti-miR-21                                                   Inhibitor   Oligonucleotide             IPF; Renal fibrosis                                         Preclinical                             Liu et al., [@B99]; Chau et al., [@B19]
                      methylation                                                      Transmethylation                                     Liver, Kidney, Lung, Heart, Skin, Gut             Ademetionine (SAM)                                            Inhibitor   Small molecule              Liver fibrosis                                              Approved\| Unknown                      NCT02231333
                                                                                       BMPER (gene)                                         Lung                                              DNA methylation                                               Inhibitor   Methylation                 IPF                                                         Preclinical                             Huan et al., [@B66]

*Drug belongs to monomer extracted from natural products*.

*Organs that had study report of corresponding targets in fibrosis treatment*.

*Clinical trial resource are from <http://Clinicaltrials.gov>*.

*Trial Identifier is the clinical trail identifier of corresponding drug*.

*mTOR, mechanistic target of rapamycin; mTORC1, mechanistic target of rapamycin complex 1; JAK-STAT, janus kinase/signal transducers and activators of transcription; PI3K-Akt, phosphoinositide 3-kinase/protein kinase B; IPF, idiopathic pulmonary fibrosis; FAK1, focal adhesion kinase 1; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IKK, I-kappa B kinase; cAMP-PKA, cyclic AMP- protein kinase A signaling; ROCK, rho-associated protein kinase; PDE, phosphodiesterase; SSc, systematic sclerosis; PPAR, peroxisome proliferator-activated receptor; FXR, farnesoid X receptor; GR, glucocorticoid receptor; ER, estrogen receptor; TGF-β, transforming growth factor-β*.

In addition, there are also some nuclear receptors located in cytoplasm and nucleus, which could be activated by small molecule agonists, such as PPAR. Rosiglitazone, a PPAR-γ agonist, has anti-fibrotic effect as a consequence of activating MMP-1 and elevating HGF expression in patients with systemic sclerosis-related interstitial lung disease (Bogatkevich et al., [@B13]). Other approved PPAR targeting drugs like Elafibranor and Pioglitazone, have entered phase II and phase I studies, respectively. Obeticholic acid is an approved drug entering phase III study that decreases inflammation and fibrosis in NASH patients via activating FXR signaling (Verbeke et al., [@B165]).

Epigenetics are very different types of fibrosis therapies. The most studied epigenetics-based therapy for fibrosis is microRNA. MicroRNA could be neutralized by specific anti-miRNA oligonucleotides delivered into cells. Among them, anti-miR-21 has been reported to inhibit miR-21 activity and ameliorate fibrosis progression through PPAR signaling in CKD (Chau et al., [@B19]). Another strategy is the intervention of DNA methylation for proteins such as BMP endothelial cell precursor-derived regulator (BMPER), which acts as the regulator of fibroblasts activation. Altering methylation on *BMPER* gene has been reported to decrease BMPER level and thus to inhibit fibroblasts activity (Huan et al., [@B66]). Besides, some drugs targeting both extracellular and intracellular factors are also incorporated (Table [3](#T3){ref-type="table"}). A majority of them are antioxidants, including an approved drug N-acetylcysteine (Zhang et al., [@B192]).

###### 

Single-component drugs targeting both extra- and intracellular factors.

  **Target**                             **Drug**                                     **Clinical trial**[^b^](#TN12){ref-type="table-fn"}   **Reference**                                                                                                                                                                 
  -------------------------------------- -------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ----------- --------------------- ------------------------------------------------------ ----------------------------- ---------------------------------------------------
  LOX[^d^](#TN14){ref-type="table-fn"}   LOXL2[^d^](#TN14){ref-type="table-fn"}       Liver, Kidney, Lung, Heart, Skin, Gut                 β-aminopropionitrile (BAPN)                            Inhibitor   Small molecule        Cardiac fibrosis                                       Preclinical                   Martinez-Martinez et al., [@B112]
                                                                                                                                            Simtuzumab (GS-6624)                                   Inhibitor   Monoclonal antibody   Liver fibrosis; IPF[^d^](#TN14){ref-type="table-fn"}   2(completed); 2(terminated)   NCT01452308; NCT01769196
  ROS[^d^](#TN14){ref-type="table-fn"}   NOX1[^d^](#TN14){ref-type="table-fn"}/NOX4   Liver, Kidney, Lung, Heart, Pancreas, Skin            GM-CT-01                                               Inhibitor   Polymer               Liver fibrosis                                         Preclinical                   Traber and Zomer, [@B161]
                                                                                                                                            GR-MD-02                                               Inhibitor   Polymer               Liver fibrosis                                         2(completed)                  NCT02421094
                                                                                                                                            GCS-100                                                Inhibitor   Polymer               Renal fibrosis                                         2(completed)                  NCT01843790
                                         ROS                                                                                                GKT137831                                              Inhibitor   Small molecule        Liver fibrosis                                         Preclinical                   Aoyama et al., [@B6]
                                                                                                                                            N-acetylcysteine[^\*^](#TN15){ref-type="table-fn"}     Inhibitor   Small molecule        IPF                                                    Approved\| Preclinical        Demedts et al., [@B35]; Zhang et al., [@B192]
                                                                                                                                            Mitoquinone                                            Inhibitor   Small molecule        Liver fibrosis                                         Preclinical                   Vilaseca et al., [@B166]
                                                                                                                                            Salvianolic acid B[^\*^](#TN15){ref-type="table-fn"}   Inhibitor   Small molecule        Liver fibrosis; Renal fibrosis; IPF                    Preclinical                   Liu et al., [@B103], [@B104]; Pan et al., [@B127]
                                                                                                                                            Resveratrol[^\*^](#TN15){ref-type="table-fn"}          Inhibitor   Small molecule        Liver fibrosis                                         3(completed)                  NCT02030977
                                         Vitamin (mimic)                              Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut       Pyridoxamine                                           Inhibitor   Small molecule        Renal fibrosis                                         2(completed)                  NCT00320060
                                                                                                                                            α-tocopherol                                           Inhibitor   Small molecule        IPF                                                    Approved\| Preclinical        Deger et al., [@B34]
                                         Collagen (mimic)                             Liver, Kidney, Lung, Skin                             IW001                                                  Inhibitor   Collagen              IPF                                                    1(completed)                  NCT01199887

*Drug belongs to monomer extracted from natural products*.

*Organs that had study report of corresponding targets in fibrosis treatment*.

*Clinical trial resource are from <http://Clinicaltrials.gov>*.

*Trial Identifier is the clinical trail identifier of corresponding drug*.

*LOX, lysyl oxidase; LOXL2, lysyl oxidase homolog 2; IPF, idiopathic pulmonary fibrosis; ROS, reactive oxygen species; NOX1, NADPH oxidase 1*.

Multi-component drugs used for fibrosis
---------------------------------------

Differed from single-component drugs that target a single protein or other simple targets, multi-component drugs contain more than one active ingredient. Traditional Chinese medicines (TCM) therapies, usually appeared as herbal formula, have been studied for thousands of years as multi-component drugs (Wang et al., [@B172]). Nowadays, single compound acting on multiple targets and multiple compounds acting on multiple targets are popular strategies in drug development (Hopkins, [@B63]). Fibrosis includes numerous complicated pathological pathways. Multi-component drugs, aiming at different targets, have the advantage in modulating these pathways simultaneously and producing synergistic effects. Moreover, multi-component drugs are expected to provide great resources for discovering new effective drug molecules. Many studies have revealed the pharmacology of multi-component drugs in the fibrosis treatment (Feng et al., [@B44]; Yang et al., [@B183]; Li and Kan, [@B95]) (Table [4](#T4){ref-type="table"}). For example, Fuzhenghuayu capsule (FZHY), a well-known multi-component drug for treating liver fibrosis, inhibits liver fibrosis and improves liver function in patients via inhibition of nuclear factor kappa-B kinase subunit β/nuclear factor κF and TGF-β signaling (Liu et al., [@B102]). Another emerging multi-component drug, Qishenyiqi (QSYQ), is under phase II clinical trial for ischemic heart failure. QSYQ attenuates cardiac fibrosis via IL-6/STAT3 and TNF-α/nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signalings and anti-apoptosis activities (Wang et al., [@B173]). Multi-component drugs act on different physiological reactions associated with fibrosis, such as inflammation and angiogenesis, leading to a systematic improvement of disease. Qushi Huayu Decoction (QHD) is a multitargeting drug that alleviates fibrosis by reducing ROS via the induction of glutathione and modulating lipid metabolism and gut barrier function (Feng et al., [@B43]).

###### 

Multi-component drugs.

  **Drug**                                                       **Clinical trial**[^a^](#TN17){ref-type="table-fn"}                                                                                                                                                                   **Reference**                                                        
  -------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ----------------------------- -----------------------------------
  Fuzhenghuayu capsule (FZHY)                                    TGF-β[^c^](#TN19){ref-type="table-fn"}/MMP-2[^c^](#TN19){ref-type="table-fn"}                                                                                                                                         Liver fibrosis                         2(completed); 4(recruiting)   NCT00854087; NCT02241616
  Qishenyiqi (QSYQ)                                              TNF[^c^](#TN19){ref-type="table-fn"}/TGF-β/β-Catenin                                                                                                                                                                  Ischemic heart failure                 2(recruiting)                 NCT02875639
  Qushi Huayu Decoction (QHD)                                    ROS[^c^](#TN19){ref-type="table-fn"}                                                                                                                                                                                  Liver fibrosis                         Preclinical                   Feng et al., [@B43]
  Herbal compound 861 (Cpd 861)                                  TGF-β/MMP-1/TIMP-1[^c^](#TN19){ref-type="table-fn"}                                                                                                                                                                   Liver fibrosis                         Preclinical                   Hou et al., [@B65]
  Xiao-Chai-Hu Tang (XCHT)                                       IL-6[^c^](#TN19){ref-type="table-fn"}/TNF-α/Bax protein                                                                                                                                                               Liver cancer                           2(completed)                  NCT00040898; Zhou et al., [@B205]
  Dahuangzhechong pill (DHZCP)                                   α-SMA[^c^](#TN19){ref-type="table-fn"}/TNF-α/IL-13/p38 MAPK[^c^](#TN19){ref-type="table-fn"}/ERK[^c^](#TN19){ref-type="table-fn"}                                                                                     Liver fibrosis                         Preclinical                   Cai et al., [@B16]
  Han-dan-gan-le                                                 ROS/collagen                                                                                                                                                                                                          Liver fibrosis                         Preclinical                   Li et al., [@B94]
  *Qianggan-Rongxian* Decoction                                  −                                                                                                                                                                                                                     Liver fibrosis                         Preclinical                   Li et al., [@B93]
  Yi-gan-kang granule                                            type I collagen/TIMP-1                                                                                                                                                                                                Liver fibrosis                         Preclinical                   Yao et al., [@B186]
  Ginkgo biloba extract                                          TGF-β                                                                                                                                                                                                                 Liver fibrosis                         Preclinical                   Ding et al., [@B37]
  Rosa laevigata Michx (RLTS)                                    ROS/CYP2El[^c^](#TN19){ref-type="table-fn"}/TGF-β/SMAD/FAK[^c^](#TN19){ref-type="table-fn"}-PI3K[^c^](#TN19){ref-type="table-fn"}-Akt[^c^](#TN19){ref-type="table-fn"}-p70S6K[^c^](#TN19){ref-type="table-fn"}/MAPK   Liver fibrosis                         Preclinical                   Dong et al., [@B39]
  Liuweiwuling (LWWL) tablets                                    TGF-β/SMAD/ NF-κB[^c^](#TN19){ref-type="table-fn"}                                                                                                                                                                    Liver fibrosis                         Preclinical                   Liu et al., [@B100]
  Xuefuzhuyu (XFZY) decoction                                    HIF-Y[^c^](#TN19){ref-type="table-fn"}/DDAH[^c^](#TN19){ref-type="table-fn"}/ADMA[^c^](#TN19){ref-type="table-fn"}/VEGF[^c^](#TN19){ref-type="table-fn"}                                                              Liver fibrosis                         Preclinical                   Zhou et al., [@B204]
  Diwu Yanggan (DWYG)                                            TGF-β/BMP-7[^c^](#TN19){ref-type="table-fn"}                                                                                                                                                                          Liver fibrosis                         Preclinical                   Shen et al., [@B148]
  Ocimum gratissimum extracts (OGEs)                             ROS/α-SMA                                                                                                                                                                                                             Liver fibrosis                         Preclinical                   Chiu et al., [@B26]
  Yin-Chiao-San (YCS)                                            ROS/TNF-α                                                                                                                                                                                                             IPF[^c^](#TN19){ref-type="table-fn"}   Preclinical                   Yen et al., [@B187]
  Renshen pingfei decoction                                      TGF-β/SMAD3                                                                                                                                                                                                           IPF                                    Preclinical                   Chen et al., [@B21]
  Hu-qi-yin                                                      TGF-β                                                                                                                                                                                                                 IPF                                    Preclinical                   Zhou et al., [@B203]
  Decoction for Strengthening Qi and Replenishing Lung (DSQRL)   --                                                                                                                                                                                                                    IPF                                    Preclinical                   Zhang et al., [@B190]
  Modified Kushen Gancao Formula (mKG)                           TGF-β/IL-6/IL-17A                                                                                                                                                                                                     IPF                                    Preclinical                   Gao et al., [@B51]
  Sho-seiryu-to (TJ-19)                                          ROS                                                                                                                                                                                                                   IPF                                    Preclinical                   Yang et al., [@B182]
  Hochu-ekki-to (TJ-41)                                          IL-5/IL-4/IFN-γ                                                                                                                                                                                                       IPF                                    Preclinical                   Tajima et al., [@B154]
  Shenlong Decoction                                             MMsP/TIMPs                                                                                                                                                                                                            IPF                                    Preclinical                   Lu et al., [@B106]
  Yupingfeng                                                     HMGB1[^c^](#TN19){ref-type="table-fn"}/TGF-β                                                                                                                                                                          IPF                                    Preclinical                   Cui et al., [@B30]
  Danggui--Buxue--Tang (DBTG)                                    TNF-α/TGF-β                                                                                                                                                                                                           IPF                                    Preclinical                   Lv et al., [@B107]

*Clinical trial resource are from <http://Clinicaltrials.gov>*.

*Trial Identifier is the clinical trail identifier of corresponding drug*.

*TGF-β, transforming growth factor-β; MMP-2, matrix metalloproteinase 2; TNF, tumor necrosis factor; ROS, reactive oxygen species; TIMP, tissue inhibitor of metalloproteinase; IL-6, interleukin-6; α-SMA, α-smooth muscle actin; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PDGF-BB, platelet-derived growth factor-BB; IPF, idiopathic pulmonary fibrosis; HMGB1, high mobility group box 1; CYP2E1, cytochrome P450 2E1; FAK, focal adhesion kinase; PI3K, phosphatidylinositol-3-kinase; Akt, amino kinase terminal; p70S6K, 70-kDa ribosomal S6 Kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; HIF-α, hypoxia inducible factors; DDAH, dimethylarginine dimethylaminohydrolase; ADMA, asymmetric dimethylarginine; VEGF, vascular endothelial grow factor; BMP-7, bone morphogenetic protein 7*.

With multiple targets being discovered, it becomes apparent that more common targets will be shared across many fibrotic diseases with common mechanisms, though some proteins will not express in special conditions. Meanwhile, there will be more chance for drug repositioning, which indicate common drugs will be shared across different targets andfibroproliferative diseases.

Perspective {#s4}
===========

Fibrosis is a common pathological process in many diseases, causing a great clinical burden in recent years. The development of state-of-the-art technologies facilitate discovery of fibrosis therapies. Multi-omics analysis provides a more convenient and systematic way for researching on disease mechanisms (Fernandes and Husi, [@B45]). The seamless combination of traditional transcriptomics approaches with emerging technologies, including proteomics (Ordureau et al., [@B125]), metabolomics (Shah et al., [@B147]), and metagenomics (Jiao et al., [@B73]), will offer unprecedented opportunities to precisely elucidating and dissecting fibrosis mechanisms. Nowadays, the application of cryo-electron microscopy (cryo-EM) in macromolecular structure determination make it easier to identify drug targets (Zheng et al., [@B202]). Compared with traditional X-ray crystallography, cryo-EM has advantage in determining the structure of more complex and flexible receptors (Huang et al., [@B67]; Zhang et al., [@B196]). Finally, with the advent of the era of big data, artificial intelligence technology, especially deep learning, provides more accurate algorithms for drug repositioning (LeCun et al., [@B90]; Alaimo et al., [@B2]). The continuous development and application of the above technologies and methods will make it possible to identify and discover more common mechanisms, targets and drugs in fibrosis.
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ECM

:   extracellular matrix

IPF

:   idiopathic pulmonary fibrosis

NAFLD

:   non-alcoholic fatty liver disease

TGF-β

:   transforming growth factor-β

IL-6

:   interleukin-6

SSc

:   systemic sclerosis

PDGF

:   platelet derived growth factor

EMT

:   epithelial-mesenchymal transition

HSC

:   hepatic stellate cell

MMPs

:   matrix metalloproteinases

α-SMA

:   α-smooth muscle actin

HGF

:   hepatocyte growth factor

TNF

:   tumor necrosis factor

STAT3

:   signal transducer and activator of transcription 3

TIMPs

:   tissue inhibitor of metalloproteinases

Hh signaling

:   hedgehog signaling

mTOR

:   mechanistic target of rapamycin

MAPK

:   mitogen-activated protein kinase

PPAR-γ

:   peroxisome proliferator activated receptor γ

FXR

:   farnesoid-X receptor

LOXL2

:   lysyl oxidase homolog 2

ROS

:   reactive oxygen species

CKD

:   chronic kidney disease

ET

:   endothelin

BMPER

:   BMP endothelial cell precursor-derived regulator

TCM

:   traditional Chinese medicines

FZHY

:   Fuzhenghuayu capsule

NFκB

:   nuclear factor kappa-light-chain-enhancer of activated B cells

QSYQ

:   Qishenyiqi

QHD

:   Qushi Huayu Decoction.

cryo-EM

:   cryo-electron microscopy.
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